Cannabis Bioscience International Holdings, Inc.

CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

Cannabis Bioscience International Holdings (OTC Pink: CBIH) announced an expanded research strategy at the intersection of endocannabinoid science and biological medicine. The company plans to investigate cannabinoids' interactions with pathways tied to immune regulation, neuroinflammation, chronic pain, autoimmune disease, and cancer biology, with an eye toward building a patentable IP portfolio. CBIH says it intends to explore research partnerships and licensing tied to anticipated federal rescheduling of marijuana to Schedule III, but the release contains no financial data, contracts, or clinical results.

•7d ago

CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research

CBIH announced the development of an intranasal nanoemulsion platform aimed at exploring cannabinoid-based treatments for Alzheimer's disease. The technology is designed to deliver neuroactive compounds across multiple pathways rather than targeting a single biological mechanism. Management cited the growing burden of Alzheimer's, with costs estimated at $409 billion in 2026, as a driver for this research initiative.

•3mo ago

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

CBIH announced the completion of patent-related work and a scientific framework linking cannabinoids and psilocybin to PTSD research. The company describes this as building a 'broader scientific foundation' for trauma-related research, focusing on stress response, neuroplasticity, and emotional regulation. No clinical trials, regulatory filings, or commercial products were announced; the update is strategic and conceptual in nature.

•4mo ago

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

CBIH has submitted the required documentation to the Texas licensing process for VitaCookies, its cannabinoid-formulated functional wellness cookie line. The product was developed over nearly two years by a multidisciplinary team including physicians and scientists, focusing on nutrition, safety, and specific wellness categories such as pain, anxiety, and menopause support. The company plans to move forward carefully with a focus on licensing, franchising, and quality control, expecting to provide further updates as it advances through the regulatory and manufacturing phases.

•4mo ago

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

Cannabis Bioscience International Holdings (CBIH) announced the completion of a patent-ready melanoma research program focused on cannabinoid science and epigenetic regulation. The initiative adds to the company's portfolio of 25 finalized patent applications, with 10 already submitted to the USPTO and 15 ready for submission. Management highlighted the upcoming DEA administrative hearing on marijuana rescheduling as a potential tailwind for the broader cannabinoid research environment.

•4mo ago